-
公开(公告)号：WO2011102627A2
公开(公告)日：2011-08-25
申请号：PCT/KR2011/000981
申请日：2011-02-15
Applicant: 전남대학교산학협력단 , 이병택 , 김일수
CPC classification number: H01L21/02631 , C30B23/08 , C30B29/22 , H01L21/02403 , H01L21/02554 , H01L21/02565
Abstract: 본 발명은 산화아연(ZnO)에 격자 정합된 자외선용 단결정 ZnMgAlO 박막 및 그 제조방법으로서, ZnO 기판을 준비하고, 산화 마그네슘(MgO)과 알루미나(Al 2 O 3 )의 혼합비가 5.5~5.7 : 1인 ZnMgAlO 박막을 스퍼터링 기법을 통해 상기 ZnO 기판 상에 성장시킴으로써, 격자 상수(원자 면간 거리)가 일치하면서도 자외선 영역에서 사용할 수 있으며 에너지 밴드 갭이 큰 ZnMgAlO 박막을 얻을 수 있다.
Abstract translation: 本发明涉及与氧化锌（ZnO）晶格匹配的用于紫外线的单晶ZnMgAlO薄膜及其制备方法。 可以得到ZnMgAlO薄膜，其可以在紫外线的范围内使用，并且通过制备ZnO衬底与晶格参数（原子晶面间距）一致而具有大的能带隙，并且生长具有 通过溅射在ZnO衬底上的氧化镁（MgO）和氧化铝（Al 2 O 3）的混合比为5.5-5.7:1。
-
公开(公告)号：KR101213133B1
公开(公告)日：2012-12-18
申请号：KR1020100015418
申请日：2010-02-19
Applicant: 전남대학교산학협력단
CPC classification number: H01L21/02631 , C30B23/08 , C30B29/22 , H01L21/02403 , H01L21/02554 , H01L21/02565
Abstract: 본발명은산화아연(ZnO)에격자정합된자외선용단결정 ZnMgAlO 박막및 그제조방법으로서, ZnO 기판을준비하고, 산화마그네슘(MgO)과알루미나(AlO)의혼합비가 5.5~5.7 : 1인 ZnMgAlO 박막을스퍼터링기법을통해상기 ZnO 기판상에성장시킴으로써, 격자상수(원자면간거리)가일치하면서도자외선영역에서사용할수 있으며에너지밴드갭이큰 ZnMgAlO 박막을얻을수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020110095769A
公开(公告)日：2011-08-25
申请号：KR1020100015418
申请日：2010-02-19
Applicant: 전남대학교산학협력단
CPC classification number: H01L21/02631 , C30B23/08 , C30B29/22 , H01L21/02403 , H01L21/02554 , H01L21/02565
Abstract: PURPOSE: A single crystal ZnMgAlO thin film for an ultraviolet ray lattice-matched with a ZnO and a manufacturing method thereof are provided to obtain a ZnMgAlO thin film with a large energy band gap by adding MgO and Al2O3 to ZnO and growing the ZnO. CONSTITUTION: A ZnO substrate is prepared. A ZnMgAlO thin film is grown on a ZnO substrate with a sputtering method. A mixing ratio of MgO to Al2O3 is 5.5 to 5.7 : 1. The process pressure is 9 to 11 mTorr. A growing temperature is 580 to 620 degrees centigrade. RF applying power is 90 to 110 W. A mixing ratio of Mg to Al is 2.7 to 2.9 : 1.
Abstract translation: 目的：提供一种用于与ZnO晶格匹配的紫外线的单晶ZnMgAlO薄膜及其制造方法，以通过向ZnO中添加MgO和Al2O3并生长ZnO来获得具有大能带隙的ZnMgAlO薄膜。 构成：制备ZnO衬底。 通过溅射法在ZnO衬底上生长ZnMgAlO薄膜。 MgO与Al2O3的混合比为5.5〜5.7:1。工艺压力为9〜11mTorr。 生长温度为580至620摄氏度。 RF施加功率为90〜110W .Mg与Al的混合比为2.7〜2.9:1。
-
4.发明授权
公开(公告)号：KR100960684B1
公开(公告)日：2010-05-31
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: 본 발명은 TREM-2(Triggering Receptor Expressed on Myeloid cells-2) 유전자 또는 단백질을 포함하는 GA733-2 항원의 발현 억제 또는 검출용 조성물 및 방법, 및 이를 포함하는 형질전환 동물, 특히 형질전환 마우스 및 이의 사용방법에 관한 것으로서, 암, 특히 대장암의 원인 규명은 물론 그의 진단, 특히 조기진단 및 치료제 개발에 크게 기여할 수 있다.
TREM-2, GA733-2, 암, 대장암, 형질전환, 동물 모델, 마우스-
公开(公告)号：KR1020090090952A
公开(公告)日：2009-08-26
申请号：KR1020080016531
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00
CPC classification number: A61K38/44 , A61K38/005 , A61K38/1774 , A61K39/395 , C12N15/62 , Y10S514/886
Abstract: A composition for regulating or detecting gamma-delta T cell or cytokines secreted by the gamma-delta T cell, which contains Axl receptor tyrosine kinase, its ligand or inhibitor is provided to regulate gamma-delta T cell and prevent or treat inflammatory bowl diseases (IBD). A composition for regulating gamma-delta T cell or a cytokine which is secreted by the gamma-delta T cell comprises an Axl receptor tyrosine kinase, its ligand or its inhibitor as an active ingredient. The composition is used for preventing and treating inflammatory bowel disease. A method for screening an agent for preventing and treating inflammatory bowel disease comprises: a step of adding a test compound in Axl receptor tyrosine kinase, its ligand or inhibitor; and a step of researching the influence of test compound on the expression or activation of Axl receptor tyrosine kinase, gamma-delta T cell, or cytokine secreted by the gamma-delta T cell.
Abstract translation: 提供用于调节或检测由含有Ax1受体酪氨酸激酶，其配体或抑制剂的γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物，以调节γ-δT细胞并预防或治疗炎性碗疾病（ IBD）。 用于调节由γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物包含Ax1受体酪氨酸激酶，其配体或其抑制剂作为活性成分。 该组合物用于预防和治疗炎症性肠病。 用于筛选用于预防和治疗炎症性肠病的药剂的方法包括：在Ax1受体酪氨酸激酶，其配体或抑制剂中加入测试化合物的步骤; 以及研究化合物对由γ-δT细胞分泌的Axl受体酪氨酸激酶，γ-δT细胞或细胞因子的表达或活化的影响的步骤。
-
公开(公告)号：KR1020090090944A
公开(公告)日：2009-08-26
申请号：KR1020080016520
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: A61K48/00 , A61K2039/585 , C12N9/12
Abstract: A method for screening therapeutic agent or suppressing tumor by regulating Axl signal is provided to increase the sensitivity of natural killer cell by the expression of LIGHT gene and induce apoptosis of tumor cell. A composition for suppressing tumor comprises LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells) (TNFSF14) or its activator as an active ingredient. The activator is Axl receptor tyrosine kinase or its ligand. The Axl ligand is an antibody to Axl antibody, gamma-carboxylated Gas-6(growth-arrest specific gene 6) or protein S. The tumor is lymphatic tumor. A method for screening agent for suppressing or treating tumor comprises: a step of adding a test compound to a LIGHT (TNFSF14) or its activator; and a step of researching the influence of the test compound on the expression or activation of LIGHT or its activator.
Abstract translation: 提供通过调节Axl信号筛选治疗剂或抑制肿瘤的方法，以通过LIGHT基因的表达增加自然杀伤细胞的敏感性并诱导肿瘤细胞凋亡。 用于抑制肿瘤的组合物包括LIGHT（与蛋白D竞争结合于T细胞上的疱疹病毒进入介导蛋白的竞争性淋巴毒素样诱导蛋白）（TNFSF14）或其活化剂作为活性成分。 活化剂是Axl受体酪氨酸激酶或其配体。 Axl配体是Ax1抗体，γ-羧化气体-6（生长停滞特异性基因6）或蛋白S的抗体。肿瘤是淋巴瘤。 用于抑制或治疗肿瘤的筛选剂的方法包括：将测试化合物加入到LIGHT（TNFSF14）或其活化剂中的步骤; 以及研究化合物对LIGHT或其活化剂表达或活化的影响的一个步骤。
-
7.发明公开
公开(公告)号：KR1020090090935A
公开(公告)日：2009-08-26
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: A composition for detecting or suppressing the expression of GA733-2 antigen containing TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein is provided to use in the investigation of cancer cause, early diagnosis of cancer and development of therapeutic agent. A composition for suppressing the expression of GA733-2 antigen comprises a TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein as an active ingredient. The expression of GA733-2 antigen in a biological sample is suppressed by adding TREM-2 gene or protein. A method for screening an agent for suppressing and treating cancer comprises: a step of adding a TREM-2 gene or protein or candidate drug which suppresses or treat cancer into transgenic animal which is transformed with TREM-2 gene; and a step of researching the influence of the candidate drug on the expression or activation of TREM-2 or GA733-2. The cancer is colon cancer.
Abstract translation: 提供了用于检测或抑制含有TREM-2（触发受体表达于骨髓细胞-2）基因或蛋白质的GA733-2抗原表达的组合物用于癌症原因的调查，癌症的早期诊断和治疗剂的发展 。 用于抑制GA733-2抗原表达的组合物包含TREM-2（以骨髓细胞-2表达的触发受体）基因或蛋白质作为活性成分。 通过添加TREM-2基因或蛋白质抑制生物样品中GA733-2抗原的表达。 用于筛选抑制和治疗癌症的药剂的方法包括：向TREM-2基因转化的转基因动物中加入抑制或治疗癌症的TREM-2基因或蛋白质或候选药物的步骤; 研究候选药物对TREM-2或GA733-2表达或激活的影响的一个步骤。 癌症是结肠癌。
-
-
-
-
-
-
Search Results
7
records
(took 0.019 seconds)
